Financials in USD. Standardized financial statements.
A compact view of how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $75.45B | $74.99B | $75.52B | $70.79B | $69.01B | $61.67B | $64.95B | $42.23B | $20.95B | $20.04B |
| Revenue Growth? | +0.6% | -0.7% | +6.7% | +2.6% | +11.9% | -5.0% | +53.8% | +101.6% | +4.6% | 0.0% |
| Cost of Revenue? | $63.99B | $62.47B | $61.33B | $57.51B | $55.78B | $51.23B | $52.08B | $32.16B | $13.06B | $13.41B |
| Gross Profit? | $11.46B | $12.52B | $14.19B | $13.28B | $13.23B | $10.44B | $12.87B | $10.07B | $7.89B | $6.62B |
| Gross Margin? | +15.2% | +16.7% | +18.8% | +18.8% | +19.2% | +16.9% | +19.8% | +23.8% | +37.7% | +33.1% |
| Operating Expenses? | $8.43B | $8.92B | $9.07B | $8.73B | $8.85B | $6.96B | $8.81B | $7.41B | $5.96B | $5.45B |
| Operating Income? | $3.02B | $3.60B | $5.12B | $5.07B | $4.79B | $3.67B | $4.06B | $3.84B | $2.46B | $1.47B |
| EBITDA? | $3.95B | $4.90B | $6.46B | $6.27B | $5.76B | $4.72B | $5.04B | $4.27B | $2.74B | $1.99B |
| Income Before Tax | $3.59B | $3.61B | $5.11B | $5.04B | $4.72B | $3.74B | $4.13B | $4.02B | $2.49B | $1.95B |
| Income Tax Expense | $612.98M | $606.85M | $851.17M | $789.87M | $754.09M | $647.45M | $687.25M | $485.01M | $374.22M | $386.38M |
| Net Income? | $2.91B | $2.84B | $4.06B | $3.97B | $3.72B | $2.92B | $3.19B | $3.44B | $2.06B | $1.51B |
| EPS? | $1.82 | $1.74 | $2.49 | $2.44 | $2.29 | $1.79 | $1.96 | $2.12 | $1.27 | $1.08 |
| Diluted EPS? | $1.82 | $1.74 | $2.49 | $2.44 | $2.29 | $1.79 | $1.96 | $2.12 | $1.27 | $1.08 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality